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ABSTRACT 
 
Colorectal cancer (CRC) is a cancer that occurs in the colon or rectum and is one of the most 
common cancer forms and a leading cause of cancer death in the Western world. The 
majority of CRCs are caused by inherited or somatic mutations in the APC gene. The ApcMin 
model is driven by a truncating mutation in the Apc gene and is considered to be one of the 
best mouse models of CRC. The aim of this thesis is to uncover novel mechanisms behind the 
initiation and progression of intestinal adenomas in ApcMin/+ mice. 
Clinical studies suggest that the transcription factor Zfp148 may play a role in CRC but the 
importance of Zfp148 for tumor development has not been properly investigated. We have 
previously shown that Zfp148 is a potent inhibitor of p53 and hypothesized that Zfp148 
deficiency may protect against CRC by increasing p53-activity. In paper I, we show that 
deletion of one or both copies of Zfp148 markedly reduces tumor formation in ApcMin/+ mice. 
The result shows that Zfp148 controls the fate of newly transformed tumor cells by 
repressing p53, and suggests that targeting Zfp148 might be useful in the treatment of 
colorectal cancer. 
Previous studies show that Zfp148 inhibits activation of p53; however, the underlying 
mechanism is not understood.   We have previously shown that transcription of Cdkn2a was 
increased in Zfp148 deficient MEFs. ARF is one of two products of Cdkn2a and is a major 
activator of the p53-pathway. Therefore, we hypothesized that Zfp148 inhibits p53 by 
repressing ARF. In paper II, we tested this hypothesis in mouse embryoblasts (MEFs) and 
found that Zfp148 regulates cell proliferation and p53 activity by repressing the transcription 
of ARF. 
Finally, we addressed the role of antioxidants. Clinical studies on the ability of dietary 
antioxidants to prevent CRC show inconsistent results. To understand the effect of 
antioxidants, we gave two types of dietary antioxidants to ApcMIn/+ mice and investigated 
tumor development. Our results indicate that dietary antioxidants have no effect on tumor 
initiation but accelerate progression of existing tumors. The result raises concerns about the 
widespread use of dietary antioxidants, especially among high risk populations. 
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